NCT04919356 is a clinical trial of G2019S LRRK2 in Parkinson's Disease, sponsored by Escape Bio, Inc..

Who is sponsoring NCT04919356?

NCT04919356 is sponsored by Escape Bio, Inc..

What drugs are being tested in NCT04919356?

Interventions in NCT04919356: G2019S LRRK2.

What condition does NCT04919356 study?

NCT04919356 studies Parkinson's Disease.

Is NCT04919356 still recruiting?

NCT04919356 is currently terminated. Last updated 18 January 2023.

Last reviewed 2023-01-18 · How we verify

NCT04919356

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Parkinson's Disease G2019S LRRK2 Genetic Testing Program

Terminated Last updated 18 January 2023

What this trial tests

trial testing G2019S LRRK2 in Parkinson's Disease in 836 participants. Terminated before completion.

Timeline

8 June 2021

Primary endpoint
5 December 2022

5 December 2022

Quick facts

Lead sponsor	Escape Bio, Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	836
Start date	8 June 2021
Primary completion	5 December 2022
Estimated completion	5 December 2022
Sites	1 location across United States

Drugs / interventions tested

G2019S LRRK2

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

Escape Bio, Inc.

Who can join

18 and older, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Increase awareness of the G2019S LRRK2 mutation in Parkinson's and no cost genetic testing program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other Escape Bio, Inc. trials

Trials by the same sponsor.

NCT05349019 — A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04919356 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Escape Bio, Inc.
Last refreshed: 18 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04919356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing